Moloney Securities Asset Management LLC Invests $513,000 in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Moloney Securities Asset Management LLC bought a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 15,465 shares of the company's stock, valued at approximately $513,000.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in Harmony Biosciences by 222.9% during the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company's stock worth $97,000 after acquiring an additional 2,022 shares during the last quarter. Swiss National Bank boosted its stake in Harmony Biosciences by 28.2% during the 4th quarter. Swiss National Bank now owns 78,200 shares of the company's stock worth $2,691,000 after acquiring an additional 17,200 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Harmony Biosciences by 50.6% during the 4th quarter. Teacher Retirement System of Texas now owns 11,801 shares of the company's stock worth $406,000 after acquiring an additional 3,964 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Harmony Biosciences by 52.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 20,221 shares of the company's stock worth $671,000 after acquiring an additional 6,915 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after acquiring an additional 1,262,362 shares during the last quarter. Institutional investors own 86.23% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on HRMY shares. The Goldman Sachs Group raised shares of Harmony Biosciences to a "hold" rating and set a $33.00 price objective on the stock in a research note on Thursday. Oppenheimer assumed coverage on shares of Harmony Biosciences in a research note on Monday, June 2nd. They set an "outperform" rating and a $61.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Needham & Company LLC restated a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a report on Tuesday, May 6th. Finally, Mizuho raised their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a report on Thursday, May 15th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $51.33.

Harmony Biosciences Stock Performance

HRMY stock traded up $0.71 during trading hours on Monday, reaching $34.71. The stock had a trading volume of 431,620 shares, compared to its average volume of 634,094. The stock has a 50-day simple moving average of $33.59 and a 200 day simple moving average of $33.87. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The stock has a market capitalization of $1.99 billion, a PE ratio of 13.25, a price-to-earnings-growth ratio of 0.47 and a beta of 0.83. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.67 and a quick ratio of 3.63.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 20.53% and a return on equity of 24.32%. The company had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same quarter last year, the firm posted $0.67 EPS. The company's quarterly revenue was up 19.5% on a year-over-year basis. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.